Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
NCT06992609 · ALBORAN Phase 3Active, not recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 71 (actual)
- Start date
- 15 Sep 2025
- Primary completion
- 30 Jun 2029 (estimated)
- Study completion
- 30 Jun 2029
- Last update posted
- 26 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Durvalumab Drug
Conditions and primary outcome
- Small Cell Lung Carcinoma
Primary outcome
To describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT. (90 days after last dose of durvalumab of the last patient.)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06992609.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06992609 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.